北京阳光诺和药物研究股份有限公司关于召开2025年第五次临时股东会的通知

Group 1 - The company will hold its fifth extraordinary general meeting of shareholders on December 12, 2025, at 14:30 [2][48] - The voting will be conducted through the Shanghai Stock Exchange's online voting system, with specific time slots for both online and on-site voting [2][5] - Shareholders must register to attend the meeting, with registration available both in person and via email [12][13] Group 2 - The company announced the transfer of 70% equity in Shanghai Meisuke Data Co., Ltd. from its wholly-owned subsidiary, Beijing Nuohuo Demai Pharmaceutical Technology Co., Ltd., to Beijing Zhongjian Peilian Medical Research Institute [21][40] - The transaction is valued at 2 million yuan, and the subsidiary will no longer hold any equity in Meisuke Data after the transfer [21][40] - The decision to transfer the equity was made to improve asset operation efficiency and reduce management costs, as Meisuke Data has been in a state of continuous loss [25][36] Group 3 - The board of directors approved the equity transfer agreement during the 27th meeting of the second board session held on November 25, 2025 [45][46] - The transaction is not classified as a related party transaction or a major asset restructuring [22][24] - The company will ensure compliance with relevant regulations and disclosure obligations regarding the transaction [42][39]